We are live on ! Find out more
PSTV

Plus Therapeutics
PSTV

Delisted

PSTV was delisted on the 31st of July, 2026.

Back to rankings

8 hedge funds and large institutions have $609K invested in Plus Therapeutics in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

33% more funds holding

Funds holding: 6 → 8 (+2)

0% more ownership

Funds ownership: 0% → 0% (+0%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

52% less capital invested

Capital invested by funds: $1.28M → $609K (-$667K)

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
1
Calls
$67K
Puts
–
Net Calls
+$67K
Net Calls Change
+$54K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$190K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$95.2K
3
Macquarie Group
Macquarie Group
Australia
+$95.2K
4
Renaissance Technologies
Renaissance Technologies
New York
+$47.6K

Top Sellers

Rank Fund Capital Flow
1
JG
Jefferies Group
New York
-$214K
2
PCM
Perkins Capital Management
Minnesota
-$143K
3
BlackRock
BlackRock
New York
-$47.6K
4
Creative Planning
Creative Planning
Kansas
-$22K
5
Northern Trust
Northern Trust
Illinois
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
1
Perkins Capital Management
Minnesota
$223K -$143K -3 -27%
Vanguard Group
2
Vanguard Group
Pennsylvania
$182K +$190K +4 +133%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$59K +$95.2K +2 New
BlackRock
4
BlackRock
New York
$35K -$47.6K -1 -50%
VF
5
Virtu Financial
New York
$34K – – –
Macquarie Group
6
Macquarie Group
Australia
$29K +$95.2K +2 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$24K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$16K +$47.6K +1 New
FIA
9
FNY Investment Advisers
New York
$4K – – –
LTFS
10
Ladenburg Thalmann Financial Services
Florida
$1K – – –
PCM
11
Princeton Capital Management
New Jersey
$1K – – –
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$1K – – –
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Quebec, Canada
$19 – – –
JG
14
Jefferies Group
New York
– -$214K -4 Closed
Bank of New York Mellon
15
Bank of New York Mellon
New York
– -$14K – –
California Public Employees Retirement System
16
California Public Employees Retirement System
California
– -$4K – –
Creative Planning
17
Creative Planning
Kansas
– -$22K – –
HighTower Advisors
18
HighTower Advisors
Illinois
– -$5K – –
IP
19
Intellectus Partners
California
– -$9K – –
MCM
20
Marathon Capital Management
Maryland
– -$3K – –
Northern Trust
21
Northern Trust
Illinois
– -$16K – –
PMFA
22
Plante Moran Financial Advisors
Michigan
– -$1K – –
William Blair & Company
23
William Blair & Company
Illinois
– -$7K – –

PSTV Hedge Fund Activity: Q2 2018 in Review

8 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q2 2018, worth a combined $609K — down 52% from $1.28M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PSTV positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $190K. The largest seller was Jefferies Group, exiting entirely with an estimated $214K sold.

  • 8 institutional investors held Plus Therapeutics (PSTV) as of Q2 2018, up from 6 in Q1 2018.
  • Funds reported $609K of Plus Therapeutics stock for Q2 2018, down 52% quarter-over-quarter.
  • 3 funds opened new Plus Therapeutics positions in Q2 2018 and 1 closed out, a net change of +2 holders.
  • The largest Plus Therapeutics buyer in Q2 2018 was Vanguard Group, an estimated $190K added.
  • The largest Plus Therapeutics seller in Q2 2018 was Jefferies Group, an estimated $214K sold.

Based on aggregated 13F filings for Q2 2018.